Identification of novel tumor antigen by using autologous-tumor specific immune responses in thoracic malignancies

分析自体肿瘤特异性免疫应答，对于发展免疫治疗作为治疗预后不良的胸部恶性肿瘤的新方法具有重要意义。在这项研究中，我们从肺癌患者中诱导了几种CTL，它们是HLA-A2或HLA-A24限制性的。其中，CTL克隆1以HLA-A24限制性方式识别自体大细胞癌细胞系以及包括肺腺癌和鳞状细胞癌的同种异体肺癌细胞系。利用自体肿瘤细胞制备的cDNA文库，通过cDNA表达克隆来分离编码CTL识别的抗原的cDNA克隆。这些方法将有助于我们开发新的模式，诊断和治疗胸部恶性肿瘤。

In order to developing immunotherapy as new modalities against thoracic malignancies with poor prognosis, it is important to analyze autologous tumor-specific immune responses. In this study, we induced several CTLs from patients with lung cancer, which are HLA-A2 or HLA-A24-restricted. Among them, CTL Clone 1 recognized the autologous large cell carcinoma cell line as well as allogenic lung cancer cell lines including adenocarcinoma and squamous cell carcinoma of the lung in an HLA-A24-restricted manner. cDNA clone coding antigen recognized by the CTL was isolated by cDNA expression cloning using cDNA library made from autologous tumor cells. These approaches will help us to develop new modalities for diagnosis and therapy for thoracic malignancies.